Skip to main content
Premium Trial:

Request an Annual Quote

Heating Up

The Boston Globe notes a recent spike in biotech merger and acquisitions. The deals going through at Inverness, Biogen, and Takeda follow an 18-month-long lull. "When you've had a cycle of fear and now we're seeing real signs that growth is coming," says Kevin Gorman from Putnam Associates, "if you can pick up an asset that fits your strategy, and you can pick it up at a decent price, why not?"